tiprankstipranks
Voyager announces selection of development candidate for GBA1 Program
PremiumThe FlyVoyager announces selection of development candidate for GBA1 Program
9d ago
Neurocrine initiates Phase 1 study of NBI-1065890
PremiumThe Fly
Neurocrine initiates Phase 1 study of NBI-1065890
28d ago
Neurocrine price target raised to $158 from $148 at JPMorgan
PremiumThe Fly
Neurocrine price target raised to $158 from $148 at JPMorgan
1M ago
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe FlyJPMorgan biotech analysts to hold an analyst/industry conference call
2M ago
Neurocrine price target raised to $159 from $128 at UBS
PremiumThe Fly
Neurocrine price target raised to $159 from $128 at UBS
2M ago
Neurocrine price target raised to $164 from $157 at Guggenheim
PremiumThe Fly
Neurocrine price target raised to $164 from $157 at Guggenheim
2M ago
Neurocrine price target raised to $140 from $127 at Wells Fargo
PremiumThe FlyNeurocrine price target raised to $140 from $127 at Wells Fargo
3M ago
Neurocrine price target lowered to $140 from $141 at Citi
PremiumThe Fly
Neurocrine price target lowered to $140 from $141 at Citi
3M ago
Neurocrine trading resumes
PremiumThe Fly
Neurocrine trading resumes
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100